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Abstract
Background: Cervical cancer (CC) is the second most common cancer in females in developing countries. The two
viral oncoproteins E6 and E7 mediate the oncogenic activities of high-risk human papillomavirus (HR-HPV), and HR-
HPV, especially HPV16 or/and HPV18 (HPV16/18) play critical roles in CC through different pathways. microRNAs
(miRNAs) may be associated with CC pathogenesis. Researches have indicated that human papillomavirus (HPV) may
regulate cellular miRNA expression through viral E6 and E7. Herein, the purposes of this study were to identify the
relationship between HPV infection and aberrantly expressed miRNAs and to investigate their pathogenic roles in CC.
Methods: miRNA expression was assessed using a microRNAs microarray in HPV16 E6- and E7-integrated HPV-negative
HT-3 cell lines and mock vector-transfected HT-3 cells. The microarray results were validated, and the expression of miR-
3156-3p was identified in HPV-positive and -negative CC cell lines as well as primary CC and normal cervical epithelium
tissues using quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Cell Counting Kit-8 (CCK8), flow
cytometry, transwell analysis, tube formation, and Western blotting were used to identify the functional role of miR-
3156-3p in CaSki, SiHa, and HeLa cell lines.
Results: Six underexpressed microRNAs (miR-3156-3p, 6779-3p, 4779-3p, 6841-3p, 454-5p and 656-5p) were consistently
identified in HPV16 E6- and E7-integrated HT-3 cells. Further investigation confirmed a significant decrease of miR-3156-
3p in HPV16/18 positive CC lesions. CCK8, flow cytometry, transwell analysis, tube formation assays, and Western blotting
of the CC cell lines with miR-3156-3p over/under-expression in vitro showed that miR-3156-3p was involved in cell
proliferation, apoptosis, migration, neovascularization, and SLC6A6 regulation.
Conclusions: Our findings indicate that miR-3156-3p plays a suppressor-miRNA role in CC and that its expression is
associated with HR-HPV infection.
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Background
CC is the second most common cancer and third lead-
ing cause of cancer death in females in less developed
countries,with nearly 90% of CC deaths occurred in de-
veloping parts of the world [1]. HPVs are considered to
be the major etiologic contributor to the development of
CC and have been associated with 99.7% of cervical car-
cinomas [2]. HPVs are a family of small double-stranded
circular DNA viruses with genomes containing 8-kb
DNA sequences. So far, more than 150 types of HPVs
have been identified. Among them, HR-HPV types 16
and 18 are the most prevalent and are responsible for
70% of CC [3]. E6 and E7 HR-HPVs are viral oncopro-
teins that inactivate p53 and pRB, respectively, and sup-
pression of these two major cellular tumor suppressors
subsequently contributes to cervical carcinogenesis.
miRNAs are small non-coding RNAs that are approxi-
mately 20 nucleotides in length and may regulate thou-
sands of mRNA targets. miRNAs are transcribed in the
nucleus and become associated with the RISC complex
* Correspondence: qdwykpro@163.com
1Department of Obstetrics and Gynecology, The Affiliated Hospital of
Qingdao University, Qingdao, China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Xia et al. Virology Journal  (2017) 14:20 
DOI 10.1186/s12985-017-0695-7
after processing. They primarily act as negative regula-
tors of gene expression by binding to their complemen-
tary mRNA targets and either repressing translation or
promoting mRNA degradation. Many studies indicate
that changes in the expression of miRNAs may be asso-
ciated with a variety of human cancers. These abnor-
mally expressed miRNAs affect the expression of various
oncogenic or tumor suppressor proteins that, in turn,
alter cellular growth, invasion, and the metastatic poten-
tial of CC cells [4]. miRNAs can function in two oppos-
ing roles by either behaving as oncogenes or tumor
suppressors depending on the tissue type and presence
of specific targets [5]. To date, mounting evidence indi-
cates that HPVs may regulate cellular miRNA expression
through viral E6 and E7 [6].
To investigate the association between abnormal
miRNA expression and HR-HPV infection in CC, we
identified miRNA expression profiles by microarray in
HPV16-E6 and -E7 integrated HPV-negative HT-3 cells
and mock infection negative controls. The microarray
results, validated by qRT-PCR, showed that miR-3156-
3p expression was remarkably decreased in HPV16-E6
or/and -E7 integrated HPV-negative HT-3 and C-33A
cell lines. Then, we examined the level of miR-3156-3p
expression by qRT-PCR in 90 cases of human cervical
tissues, including normal cervical epithelium and HPV-
positive and HPV-negative cervical cancer tissues. We
also detected a miR-3156-3p effect on the carcinogenetic
processes in the CC cell lines. In addition, we validated a
predicted target gene, SLC6A6, for miR-3156-3p with in
vitro experiments and CC tissues. The aim of our study
was to explore the role and mechanism of miR-3156-3p
during cervical carcinogenesis induced by HR-HPV
infection.
Results
Identification of miR-3156-3p as an aberrantly expressed
miRNA in HR-HPV infected CC
The transfection efficiency was tested by western blotting,
which revealed that the transfected cells successfully
expressed the E6, −E7, or -E6/E7 proteins (Fig. 1a). Using
a microRNA microarray analysis, six downregulated miR-
NAs (miR-3156-3p, 6779-3p, 4779-3p, 6841-3p, 454-5p
and 656-5p) were consistently found in HT-3E6/E7 cells
compared to HT-3 V cells (Fig. 1b and c). A qRT-PCR
analysis showed that miR-3156-3p was underexpressed in
HPV16 E6- and E7-integrated HT-3 and C-33A cells. In
HPV16 E6- and E7-integrated HT-3 cells, including HT-
3E6, HT-3E7, and HT-3E6/E7, the level of miR-3156-3p
was significantly lower than the level in HT-3 V. Yet, there
was no difference between HT-3E6, HT-3E7, and HT-
3E6/E7, as shown in Fig. 1d. A similar result was found in
the C-33A cell line (Fig. 1d).
In addition, we examined the level of miR-3156-3p ex-
pression in normal cervical tissues and CC tissues, in-
cluding 10 HPV-negative cases and 40 HPV16/18
positive cases. The results showed that miR-3156-3p ex-
pression was reduced in CC tissues compared to expres-
sion in normal cervical tissues (Fig. 1e). Furthermore,
miR-3156-3p expression was lower in HPV16/18 positive
cervical cancer than expression in HPV-negative lesions
(Fig. 1e). However, there was no significant difference
between HPV16-positive CC tissues (n = 26) and
HPV18-positive CC tissues (n = 14) (Fig. 1f ). Our find-
ings suggest that miR-3156-3p probably contributes to
cervical carcinogenesis and its reduction of miR-3156-3p
expression in cervical cancer might be associated with
HR-HPV infection.
Altered miR-3156-3p expression influenced apoptosis,
migration, invasion and tube formation of CC cells
To delineate the role of miR-3156-3p in cervical car-
cinogenesis, we modulated miR-3156-3p expression by
transient transfection with mimics and an inhibitor.
The up-regulation and down-regulation of miR-3156-
3p in Hela, SiHa, Caski Cells were confirmed using
qRT-PCR (Fig. 2a). We examined the influence of
miR-3156-3p on cell growth, apoptosis, migration, in-
vasion and tube formation in CC cell lines.
First, we measured cellular proliferation using a CCK8
assay after cells were transfected with miR-3156-3p
mimics or an inhibitor for 24, 48, 72 and 96 h. No sig-
nificant difference in the proliferation rate was observed
in Hela, Siha and Caski cells 24 h after transfection.
However, 48 h after transfection with miR-3156-3p
mimics, we noticed the rate of growth were 30%, 21%
and 42%, respectively, less than that in NC group in
Hela, Siha and Caski cells, (Fig. 2b). Conversely, after
24 h and 48 h transfections with and miR-3156-3p in-
hibitor, cellular proliferations were significantly higher
than that in inhibitor-NC group in those 3 cell lines
(Fig. 2b). More specifically, downregulation of miR-
3156-3p resulted in a 13%, 38% and 5% increase in the
cellular proliferation rate at 48 h and led to a 10%, 40%
and 22% increase at 72 h in Hela, Siha and Caski cells,
respectively (Fig. 2b).
Furthermore, the apoptosis rates of Hela, SiHa and
Caski cells transfected with miR-3156-3p mimics or an
inhibitor were examined using Annexin-V-FITC and a
PI assay. As Fig. 2c shows, the apoptosis rate at 48 h
after transfection significantly increased in Hela, Siha
and Caski cells transfected with miR-3156-3p mimics
and decreased in CC cells transfected with a miR-3156-
3p inhibitor compared to the corresponding negative
controls (all p < 0.05).
To demonstrate that miR-3156-3p participates in the
regulation of migration and invasion in CC, we used
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Caski cells that were transfected with miR-3156-3p
mimics or an inhibitor to assess cell migration and inva-
sion using the transwell chamber assay. The results
showed that migration and invasion significantly in-
creased in the inhibitor group and decreased in the
mimics group compared to the negative control groups
(p < 0.01 vs control, Fig. 3a and b).
To assess the capacity of miR-3156-3p on CC cells to
mimic a vasculature network on Corning Matrigel, Caski
cells were seeded on three-dimensional matrices after a
48 h transfection. We found that Caski cells in the in-
hibitor group were able to form several tubular struc-
tures, although the structures were less organized
(Fig. 3c). In contrast, miR-3156-3p mimics completely
abrogated the ability of Caski cells to form capillary
structures (Fig. 3c).
Overall, our data indicates that miR-3156-3p modu-
lates CC cell proliferation, apoptosis, migration, invasion
and vasculogenic activity.
miR-3156-3p negatively regulated SLC6A6 expression at
the post-transcriptional level
SLC6A6 was selected as a predictive target of miR-
3156-3p through TargetScan, PicTar and miRBase
software. The effect of miR-3156-3p on SLC6A6
mRNA and protein expression was tested in both
Caski and SiHa cells using qRT-PCR, Western blot
analysis, and transfection with a miR-3156-3p inhibi-
tor or mimics. We found that miR-3156-3p mimics
significantly inhibited SLC6A6 protein expression in
both SiHa and Caski cells (Fig. 4a), whereas downregula-
tion of miR-3156-3p caused a higher expression of
SLC6A6 protein in Caski cells at 72 h post-transfection
(Fig. 4a). There were no significant changes in the mRNA
levels of SLC6A6 (Fig. 4b). Our findings suggest that
SLC6A6 is negatively regulated by miR-3156-3p at the
post-transcriptional level in CC cells.
To confirm that SLC6A6 was directly inhibited by
miR-3156-3p, a dual-luciferase reporter system was used.
We found that miR-3156-3p mimics markedly inhibited
the firefly luciferase reporter activity of the wild-type
SLC6A6 3’-UTR, but did not change the activity of the
mutant 3’-UTR constructs (Fig. 4c). The results suggest
that miR-3156-3p inhibited SLC6A6 expression by bind-
ing to the SLC6A6 3’- UTR.
The expression of SLC6A6 increased in CC tissues
SLC6A6 mRNA and protein expression levels were
tested in 40 HPV-positive CC tissues and 40 normal cer-
vical tissues with qRT-PCR and immunohistochemical
staining. As shown in Fig. 5a-b, the SLC6A6 mRNA level
was significantly higher in HPV-positive CC samples
compared to normal cervical samples (Fig. 5a). In im-
munohistochemical analysis, the positive expression of
the SLC6A6 protein was primarily localized to the
cell membrane. As shown in Fig. 5b, SLC6A6 protein
expression was markedly higher in CC compared to
normal cervix tissue.
DNA methylation is another form of epigenetic modi-
fication. To evaluate whether DNA methylation was in-
volved in SLC6A6 gene expression in CC, a BGS assay
was performed to examine the methylation status of the
promoter region of SLC6A6 in HPV-positive and HPV–
negative CC cell lines, including Hela, SiHa, Caski, HT-3
and C-33A cells, as well as CC samples and normal cer-
vical samples. As shown in Fig. 6a, 49 individual CpG
sites within CpG island regions were sequenced to iden-
tify methylated cytosine residues. The results of SLC6A6
promoter methylation showed no significant differences
between CC samples and normal cervical samples(9.2%
vs. 12.9%). SLC6A6 promoter hypomethylation was also
found in both HPV-positive Hela, SiHa and Caski cells
and HPV-negative HT-3 and C33A cells (Fig. 6b).
Discussion
Persistent human papillomavirus infection is the main
etiological agent in CC initiation and progression [7].
The central core of HPV E6 and HPV E7 is the binding
and inactivation of the tumor suppressor proteins p53
and pRB, respectively, which affect the molecular path-
ways involved in cervical carcinogenesis [8]. However,
HPV is a necessary- but not sufficient- cause for cervical
carcinogenesis [7]. Recently, accumulating evidence has
shown that aberrant expression of cellular oncogenic
and tumor suppressive miRNAs have an important role
in cervical carcinogenesis. Using a miRNA microarray,
we found that miR-3156-3p expression was downregu-
lated significantly in HPV16 E6- and E7-integrated HT-3
cells compared to a negative control. Using a qRT-PCR
assay, we confirmed miR-3156-3p expression was down-
regulated in HPV16 E6- and E7-stable-transfected HT-3
and C33A cell lines. miR-3156-3p is the mature
(See figure on previous page.)
Fig. 1 miR-3156-3p was aberrantly expressed in HR-HPV infected cervical cancer. a The transfection efficiency was tested by western blotting,
which revealed that the transfected cells successfully expressed the E6, −E7, or -E6/E7 proteins. b-c From the microarray results, miR-3156-3p was
selected as an aberrantly expressed miRNA in HPV16 E6- and E7-integrated HT-3. d The downregulation of miR-3156-3p was validated in HPV16
E6- and E7-integrated HT-3 and C-33A cells using qRT-PCR. e miR-3156-3p expression in clinical samples was evaluated using qRT-PCR. f miR-
3156-3p expression in HPV16-positive and HPV18-positive clinical samples were evaluated using qRT-PCR. RNU6 served as the endogenous control
for miRNAs. (**p < 0.01, *p < 0.05)
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sequence of miR-3156-1 and miR-3156-2, which are
located on chromosomes 10 and 28, respectively. miR-
3156-3p annotations in miRbase came from a deep-
sequencing analysis of breast cancer in 2010 [9].
However, the function of miR-3156-3p is still unknown.
In this study, we identified miR-3156-3p expression in
normal cervical epithelium, HPV-negative and HPV16/
18-positive CC using RT-PCR. Then, reduced miR-3156-
3p expression was found in CC tissues and its expression
in HPV-positive tumors was the lowest among three
groups. We therefore presumed that reduction of miR-
3156-3p expression was involved in cervical carcinogen-
esis induced by HR-HPV infection.
To study the functional role of miR-3156-3p in CC,
we modulated miR-3156-3p expression in CC in vitro
using miRNA mimics and an inhibitor. We found that
upregulation of miR-3156-3p expression distinctly inhib-
ited cell growth and increased cell apoptosis in HPV18-
positive Hela cells and HPV16-positive SiHa and Caski
cells. Conversely, downregulation of miR-3156-3p ex-
pression remarkably promoted cell growth and de-
creased cell apoptosis in all three cell lines. Furthermore,
our results clearly demonstrated that miR-3156-3p sig-
nificantly suppressed immigration and invasion in Caski
cells. Some recent studies implicate miRNAs in the
regulation of various aspects of angiogenesis [10, 11].
Vascular mimicry is thought to foster cancer progression
by contributing to the delivery of a nutrient supply to
starved tumors and increasing cancer cell dissemination
[12]. In this study, we found that transfection with miR-
3156-3p mimics resulted in significant impairment of
tube-forming activity in Caski cells. Thus, our combined
results suggest that miR-3156-3p acts as an inhibitor of
cervical cancer tumorigenesis.
Mechanisms by which microRNAs can regulate gene
expression are still not fully understood, including mes-
senger RNA degradation, translation inhibition, pro-
moter binding, protein binding, or direct interaction
with other non-coding RNAs [13]. It is now well known
that abnormally expressed miRNA primarily functions
as a negative regulator of target gene expression through
full or partial complementary binding to the 3’-UTR,
which leads to mRNA cleavage or mRNA translation re-
pression [14]. In the present study, a bioinformatics
Fig. 2 miR-3156-3p influenced cervical cancer cells proliferation and
apoptosis. a The up-regulation and down-regulation of miR-3156-3p
were confirmed using qRT-PCR in Hela, SiHa, Caski Cells transfected
with mimics, inhibitor and corresponding negative controls (scrambled
miRNAs). RNU6 served as the endogenous control for miRNAs. b Effect
of miR-3156-3p mimics and inhibitor on HeLa, SiHa and Caski cell
proliferation in a CCK8 assay. c Effect of miR-3156-3p mimics and an
inhibitor on HeLa, SiHa and Caski cell apoptosis detected with flow
cytometry. (**p < 0.01 vs. controls, *p < 0.05 vs. controls)
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search for potential target genes of miR-3156-3p was
performed using 3 common databases, and SLC6A6 was
identified as a possible target. Dual luciferase reporter
gene activity confirmed that miR-3156-3p could target
the 3’-UTR of SLC6A6 directly. From Western blot ana-
lysis of the CC cells with miR-3156-3p overexpression or
underexpression, SLC6A6 consistently had a negative
correlation with the expression of miR-3156-3p at the
protein level but not the mRNA level.
SLC6A6 (also referred to as TauT) is a high-affinity,
low-capacity, multi-pass membrane protein that trans-
ports taurine and β-alanine in a Na+- and Cl−-dependent
manner [15]. SLC6A6 signaling has also been shown to
affect cell proliferation and cell survival [16]. Han and
colleagues demonstrated that SLC6A6 overexpression
protects kidney cells against cisplatin-induced cell death
through p53 activation [17, 18]. A recent study found
that SLC6A6 plays an important role in the maintenance
of side population cells and their cancer stem cell prop-
erties, including enhanced prosurvival activity, tumor
initiation and chemoresistance in colorectal cancer [19].
Tastesen et al. showed that knockdown of TauT leads to
a significant increase in apoptosis following cisplatin ex-
posure and that cisplatin resistance correlated with
increased TauT expression/activity [20]. Accordingly,
Sørensen BH et al. found that acquired resistance in hu-
man ovarian A2780 cancer cells correlates with in-
creased TauT activity [21]. Consistent with these reports,
Fig. 3 miR-3156-3p influenced cervical cancer cell migration, invasion and tube formation. The results showed that migration (a), invasion (b) and
tube formation (c) significantly increased in the inhibitor group and decreased in the mimics group compared to the negative control groups.
Arrow indicates tubular structure. (**p < 0.01 vs. controls, *p < 0.05 vs. controls)
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Fig. 4 miR-3156-3p downregulates SLC6A6 expression at the post-transcriptional level in cervical cancer cells. a Protein level of SLC6A6 was detected by
Western blot in Caski and SiHa cells transfected with miR-3156-3p inhibitor and mimics along with corresponding negative controls, respectively. b SLC6A6
mRNA level was examined by qRT-PCR in Caski and SiHa cells transfected with a miR-3156-3p inhibitor, mimics and corresponding controls. c HEK293 cells
were co-transfected with miR-3156-3p and WT or Mut SLC6A6 3’UTR luciferase reporter construct. (**p< 0.01 vs. controls, *p< 0.05 vs. controls)
Fig. 5 SLC6A6 expression in cervical cancer tissues. a SLC6A6 mRNA level was examined by qRT-PCR in cervical cancer and normal cervical tissue.
b Immunohistochemical staining of the anti-SLC6A6 antibody in cervical cancer and normal cervical tissues. Strong SLC6A6 immunoreactivity was
found in both the cytomembrane and cytoplasm in tumor tissues but not in the normal cervix tissues (scale bar, 100 μm). (**p < 0.01, *p < 0.05)
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our study showed that both mRNA and protein expres-
sion levels of SLC6A6 were significantly higher in CC
tissues compared to normal cervical tissues, and
SLC6A6 may play an important role in cervical carcino-
genesis. However, the regulation mechanism of SLC6A6
expression is still less understood and require further
study. Related researches found SLC6A6 gene could be
repressed by the p53 tumour suppressor gene and be
transactivated by proto-oncogenes such as WT1, c-Jun,
and c-Myb [17, 22]. Our findings suggest the expression
of SLC6A6 was regulated by miR-3156-3p at post-
transcriptional level in vitro. Additionally, SLC6A6
expression seems to be unaffected by methylation regula-
tion. Meanwhile, the tumor-suppressor effect of miR-
3156-3p may be due to the regulation of SLC6A6 in
cervical cancer. Therefore, miR-3156-3p may be a promis-
ing therapeutic strategy for CC.
Conclusions
In conclusion, our findings indicated that miR-3156-
3p plays a tumor-suppressor role in CC and its down-
regulation is associated with CC pathogenesis through
promotion of proliferation,migration,invasion and tube
Fig. 6 Promoter methylation of SLC6A6 in cervical cancer cell lines and tissue samples detected with BGS. a BGS analysis of the SLC6A6 promoter in CC
cell lines. Each circle is one CpG site and filled circles are methylated CpG sites. There are 49 CpG sites in the BGS region. b The SLC6A6 methylation rate
in cervical cancer cell lines and tissue samples. The methylation ratio of Hela, SiHa, Caski, and HT-3 cells as well as cervical cancer tissues and normal cervix
tissues was 3.7%, 16.0%, 14.3%, 11.2%, 0.7%, 9.2% and 12.9%, respectively
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formation. miR-3156-3p may be a novel therapeutic
strategy for the treatment of CC.
Methods
Clinical samples and HPV-DNA detection and genotyping
Forty HPV16/18-positive cervical cancer, 10 HPV-negative
cervical cancer and 40 HPV16/18-negative normal cervical
tissues were provided by the Affiliated Hospital of Qingdao
University (Qingdao, China). The use of tissue specimens
was approved by the Hospital Research Ethics Committee
and informed consent was obtained from patients. All tis-
sues were histologically and independently diagnosed by
two pathologists, and CC was classified histopathologically
according to the International Federation of Gynecology
and Obstetrics (FIGO) staging system [23]. All tissue sam-
ples were immediately frozen in liquid nitrogen after surgi-
cal removal and stored at −70 °C until use.
Cervical HPV infection was detected with the presence
of HPV DNA by PCR amplification using general
primers sets MY09/MY11, GP5+/6+ and SPF1/2(RIBO-
BIO,Guangzhou, China) [24–26]. The HPV-detection re-
sults of the three methods were all consistent, and the
negative samples were designated as HPV-negative sam-
ples. The positive samples were further tested with
HPV-type-specific PCR for genotypes 16 and 18 [27, 28].
The PCR protocol details are available from the corre-
sponding author.
Cell lines and transfection
The HPV16/18-positive CC cell lines HeLa, CaSki, SiHa
and the HPV-negative CC cells C33A and HT-3 were
obtained from Shanghai Institute for Biological Sciences
and the Chinese Academy of Sciences Institute of Cell
Resource Center (Shanghai, China). In the present study,
we established ectopically expressed HPV16 E6, −E7,
and -E6/E7 cell models of C33AE6, C33AE7, C33AE6/
E7, HT-3E6, HT-3E7, and HT-3E6/E7 by transfecting
HPV16 E6, −E7, and -E6/E7 oncogenes with lentivirus
vectors into the HPV-negative C33A and HT-3 cells in
our lab. The C33A-vector (C33A-V) and HT-3 vector
(HT-3 V) cells were established by transfecting C33A
and HT-3 cells with lentivirus vectors that did not code
for the HPV16 E6, −E7, or -E6/E7 proteins as controls.
Stable transfections were treated with 10 μg/ml puro-
mycin for 3 weeks. The transfection efficiency was tested
with Western blotting, which revealed that the trans-
fected cells successfully expressed E6, −E7, or -E6/E7
proteins. All cells were maintained in a humidified
incubator set at 37 °C and 5% CO2. The miRNA
expression profiles were identified in HT-3E6/E7, HT-
3 V and HT-3 cell lines using an LC Sciences micro-
RNA microarray(Hangzhou, China) containing 2578
human mature microRNAs based on Sanger miRBase
Release 20.0. Differentially expressed miRNAs were
identified by fold changes as well as by p-values that
were calculated by t-test. The threshold that was set
for up-regulated and down-regulated miRNAs was a
fold change ≥4 and a p value <0.01.
miR-3156-3p mimics and inhibitor
miR-3156-3p mimics (chemically double-stranded
oligonucleotides, 5′-CUC CCA CUU CCA GAU CUU
UCU-3′), miR-3156-3p hairpin inhibitor (single-stranded
chemically modified oligonucleotides, 5'-AGA AAG
AUC UGG AAG UGG GAG-3') and corresponding
negative controls were purchased from GenePharma
(Shanghai, China). The result of blast analysis indicated
the mimics and inhibitor were specific and potent to
miR-3156-3p using NCBI blast (Fig. 7). Negative con-
trols were a random sequence which had been exten-
sively tested in human cell lines and tissues and
validated to not produce identifiable effects on known
miRNA function. FAM dye-labeled negative controls
had the same oligonucleotide sequence as unlabeled
negative control and were used to monitor transfection
efficiency. Transient transfections were performed when
the cells reached 30-50% confluence using the RNAi-
Mate transfection reagent (GenePharma, Shanghai,
China) according to the manufacturer’s instructions. At
the indicated times after transfection, the cells were har-
vested and used in experiments.
RNA isolation and qRT-PCR for miR-3156-3p
SYBR Green-based real-time quantification of miRNAs
was used to determine miR-3156-3p expression as previ-
ously described. Total RNA was extracted using the Trizol
reagent (Invitrogen). The quality of total RNA is assessed
by ultraviolet spectrophotometer, the total RNA ration of
A260/A280 between 1.8 and 2.0 was considered as high
quality. Then, 1 μg of total RNA was subsequently
reverse-transcribed to cDNA with a miR-3156-3p-specific
stem-loop-like RT primer(RIBOBIO,Guangzhou, China)
following the manufacturer’s protocol. Then, qRT-PCR
was performed using SYBR Green mix with primers spe-
cific to miR-3156-3p(RIBOBIO,Guangzhou, China). Small
nuclear RNA RNU6 was used as an endogenous control.
Relative quantification of the miRNA expression was cal-
culated with the 2-ΔΔCT method.
qRT-PCR for mRNA
cDNAs were synthesized using a transcriptor first strand
cDNA synthesis kit (Roche). Then, qRT-PCR for mRNA
was performed using FastStart Universal SYBR Green
Master (Roche). The primers used for qRT-PCR include,
for SLC6A6, forward 5’- GCT TCC CGT ACC TCT
GCT AC-3’ and antisense 5’-TGG CCT ATG ATG ATC
TCC AA-3’. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was used as an endogenous control. Relative
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quantification of the mRNA expression was calculated
with the 2-ΔΔCT method.
Cell proliferation assay and apoptosis analysis
Cell proliferation was assessed with a Cell Counting Kit-
8 (CCK-8) assay kit (Dojindo, Japan). Hela, Siha and
Caski cells were separately cultured in 96-well plates
overnight at a density of 5000 cells/well then transfected
with miR-3156-3p mimics or an inhibitor as described
above. At 1, 2, 3, 4 and 5 days after transfection, 10 μl of
CCK8 solution was added to each well for 1 h and ab-
sorbance readings at 450 nm were obtained in triplicate
using a spectrophotometric plate reader. The data were
obtained from the measurement of 4 replicate wells for
each data point.
For the apoptosis analysis, cells were harvested after
transfection for 48 h by trypsinization, washed twice
using cold PBS and were subsequently stained with
Annexin V-FITC and propidium iodide using Annexin V
apoptosis detection kit FITC (ebioscience,San Diego, CA
92121 USA) at room temperature, and apoptosis analysis
was performed with FACS flow cytometry (BD
Biosciences, Franklin Lakes, NJ).
Transwell migration and invasion assay
Caski cells were harvested by trypsinization/EDTA. Ali-
quots of cells (1.5 × 105) were placed into transwell
chambers(Corning Incorporated, USA) for migration
assay, and 1 × 104 cells were placed into upper chambers
coated with 150 mg Matrigel for invasion assay. The
lower chambers were filled with DMEM containing 10%
FBS. After incubation at 37 °C for 12–24 h, cells
remaining on the upper surface of the membrane were
removed. Cells on the lower surface of the membrane
were fixed and stained with crystal violet. Then stained
cells were visualized and counted under a light micro-
scope. The assays were performed in triplicate.
Tube formation assay
To assess tube formation, 50 μl Matrigel (Corning
Incorporated,USA) was plated to 96-well plates at a
horizontal level and incubated for 30 min at 37 °C.
Then Caski cells after transfection for 24 h were har-
vested, re-suspended with serum-free DMEM and
loaded on the top of the Matrigel at a density of 1.5
x 104 cells per well. Each conditional group contained
4 wells. Following incubation at 37 °C for 12 h, each
well was analyzed directly under a microscope. Under
a microscope with 10x phase contrast, tubules in each
field were imaged and an average of tubules from 3
random fields in each well was counted. The assays
were repeated three times.
Western blot analysis
Cells were washed twice with ice-cold PBS and treated
with RIPA lysis buffer. Protein concentrations were
quantified by the BCA protein assay kit (Beyotime,
Haimen, China). Protein were separated on 8% SDS-
PAGE gels, transferred onto PVDF membranes (Bio-
Rad, Hercules, CA, USA) and blocked for 1 h at room
temperature. Membranes were probed with primary
antibodies anti-SLC6A6 (1:1000 dilution; Abcam,
USA) at 4 °C overnight followed by incubation with
HRP-conjugated secondary antibodies. Each sample
was also treated with anti-β-actin antibody (Sigma-Al-
drich) as a control. Blots were detected using an ECL
detection system.
Fig. 7 Sequence alignments of miR-3156-3p mimics and inhibitor were assessed using NCBI blast
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Tissue samples immunohistochemistry
Paraffin-embedded tissue blocks were sectioned (4 μm)
for immunohistochemical staining. After antigen re-
trieval and peroxidase blocking, the sections were incu-
bated with rabbit polyclonal antibody against human
SLC6A6 (1:50 dilution; Abcam, USA) at 4 °C overnight.
After 3 washings in sterile phosphate-buffered saline,
sections were incubated with a horseradish peroxidase
(HRP)-conjugated antibody against rabbite immuno-
globulin G (IgG) (Invitrogen, Carlsbad, Calif ) (1 : 1000
dilution). Isotype-matched IgG control was used in each
experiment. The percentage of positive cells was graded
according to the following criteria: 0, less than 10%; 1,
10–30%; 2, 30–50%; or 3, more than 50%[29].
Bisulfite genomic sequencing (BGS)
Genomic DNA was extracted from cells and tissue speci-
mens using the phenol-chloroform method. Bisulfite treat-
ment was performed using a CpGenomeTM Universal
DNA Modification Kit (Millipore, USA), following the
manufacturer’s instructions. Modified DNA was amplified,
and PCR products were gel-purified and sub-cloned into a
pTG19-T vector system (MAP BIOTHCH, China). Ten
colonies were sequenced to assess the degree of methyla-
tion at each CpG site. The primers used for SLC6A6 PCR
were listed: forward 5’-GGT AAG GTT AGG ATT TTG
GAG TTT T-3’, antisense 5’-TCA ACA TCA CCC ATC
CTA AATA -3’.
Dual-luciferase reporter assay system
For luciferase reporter, the 3’UTR of SLC6A6 containing
the putative binding sites for miR-3156-3p (682 bp) or a
mutant lacking the miR-3156-3p seed sequences was amp-
lified by PCR and cloned into the pmiR-RB-REPORT vector
to generate reporter constructs (RIBOBIO,Guangzhou,
China). Constructs were verified by sequencing. Trans-
fection of miR-3156-3p mimics was performed when
HEK293 cells were grown to 50-70% confluence (Invi-
trogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. Cells were harvested 48 h after
co-transfection and assayed with the Dual Luciferase
Assay kit (Promega, Madison, WI, USA) according to
the manufacturer’s protocol.
Statistical analysis
SPSS17.0 statistical software package was used for statis-
tical analysis. Experiments were repeated independently
at least three times, and the results are expressed as
mean ± SD. Statistical differences between groups were
evaluated using Student's paired two tailed t- test. p <
0.05 was considered statistically significant.
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